Death
|
100.0
|
2
|
22
|
1
|
11
|
0.004
|
Subsequent re-transplants
|
100.0
|
1
|
26
|
5
|
4
|
0.739
|
Living Donor
|
100.0
|
4
|
18
|
5
|
9
|
0.285
|
BMI >30 kg/m2
|
100.0
|
0
|
32
|
2
|
1
|
0.564
|
Diabetes
|
100.0
|
0
|
32
|
2
|
2
|
1.000
|
Alcohol abuse
|
100.0
|
0
|
34
|
2
|
0
|
n.d.
|
Active Smoking
|
100.0
|
0
|
31
|
2
|
3
|
0.655
|
COPD
|
100.0
|
0
|
35
|
1
|
0
|
n.d.
|
Recipient EBV IgG at Tx
|
86.1
|
12
|
13
|
4
|
2
|
0.414
|
Recipient CMV IgG at Tx
|
91.7
|
9
|
15
|
6
|
3
|
0.317
|
Donor CMV IgG at Tx
|
97.2
|
13
|
8
|
5
|
9
|
0.285
|
Recipient Anti-HCV at Tx
|
61.1
|
0
|
22
|
0
|
0
|
n.d.
|
Anti-CMV treatment after Tx
|
100.0
|
10
|
9
|
7
|
10
|
0.467
|
Ganciclovir/valganciclovir after Tx
|
100.0
|
9
|
11
|
7
|
9
|
0.617
|
Pre-transplant malignancy
|
100.0
|
2
|
34
|
0
|
0
|
1.000
|
Pre-transplant HCC
|
100.0
|
2
|
34
|
0
|
0
|
1.000
|
Non-PTLD malignancy after Tx
|
100.0
|
0
|
31
|
2
|
3
|
0.655
|
Breast cancer after Tx
|
100.0
|
0
|
35
|
0
|
1
|
n.d.
|
Pre-transplant dialysis
|
100.0
|
12
|
20
|
2
|
2
|
1.000
|
Donor HLA A26, B38
|
75.0
|
0
|
25
|
0
|
2
|
n.d.
|
Donor HLA A1
|
75.0
|
1
|
15
|
5
|
6
|
0.763
|
Donor HLA B8
|
75.0
|
1
|
21
|
3
|
2
|
0.655
|
Donor HLA DR3
|
75.0
|
1
|
20
|
4
|
2
|
0.414
|
Recipient HLA A26, B38
|
52.8
|
0
|
18
|
0
|
1
|
n.d.
|
Recipient HLA A2
|
52.8
|
6
|
2
|
10
|
1
|
0.007
|
Recipient HLA A11
|
52.8
|
0
|
15
|
3
|
1
|
0.317
|
Recipient HLA B5
|
52.8
|
0
|
15
|
2
|
2
|
1.000
|
Recipient HLA B18
|
52.8
|
0
|
16
|
3
|
0
|
n.d.
|
Recipient HLA B21
|
52.8
|
0
|
18
|
1
|
0
|
n.d.
|
Recipient HLA B35
|
52.8
|
1
|
12
|
4
|
2
|
0.414
|
Recipient HLA A3
|
52.8
|
1
|
10
|
4
|
4
|
1.000
|
Recipient HLA DR27
|
52.8
|
0
|
19
|
0
|
0
|
n.d.
|
HLA A locus mismatching
|
47.2
|
7
|
2
|
3
|
5
|
0.480
|
HLA B locus mismatching
|
47.2
|
10
|
0
|
3
|
4
|
0.706
|
HLA DR locus mismatching
|
47.2
|
12
|
2
|
2
|
1
|
0.564
|
Anti-thymocyte globulin after Tx
|
86.1
|
0
|
30
|
1
|
0
|
n.d.
|
Basiliximab therapy after Tx
|
86.1
|
6
|
11
|
7
|
7
|
1.000
|
Daclizumab therapy after Tx
|
86.1
|
0
|
29
|
1
|
1
|
1.000
|
Tacrolimusc after Tx
|
100.0
|
5
|
18
|
3
|
10
|
0.052
|
Ciclosporinec after Tx
|
100.0
|
17
|
5
|
10
|
4
|
0.109
|
MMFc after Tx
|
100.0
|
10
|
15
|
5
|
6
|
0.763
|
Myforticc after Tx
|
100.0
|
0
|
35
|
0
|
1
|
n.d.
|
Steroidsc after Tx
|
100.0
|
32
|
1
|
1
|
2
|
0.564
|
Sirolimusc after Tx
|
100.0
|
0
|
34
|
1
|
1
|
1.000
|
Everolimusc after Tx
|
100.0
|
0
|
34
|
1
|
1
|
1.000
|
Azathioprinc after Tx
|
100.0
|
1
|
33
|
2
|
0
|
0.157
|
Tacrolimus at PTLDd
|
100.0
|
7
|
14
|
6
|
9
|
0.439
|
Ciclosporine at PTLDd
|
100.0
|
12
|
12
|
9
|
3
|
0.083
|
CNI-free treatment at PTLDd
|
100.0
|
1
|
30
|
1
|
4
|
0.180
|